Search tips
Search criteria 


Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
BMC Cancer. 2012; 12: 276.
Published online Jul 3, 2012. doi:  10.1186/1471-2407-12-276
PMCID: PMC3472165
Association of estrogen receptor beta variants and serum levels of estradiol with risk of colorectal cancer: a case control study
Huanlei Wu,#1 Li Xu,#4 Jigui Chen,3 Junbo Hu,2 Shiying Yu,1 Guangyuan Hu,1 Liu Huang,1 Xiaoping Chen,corresponding author2 Xianglin Yuan,corresponding author1 and Guojun Li4,5
1Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, Hubei, China
2Department of Surgery, Tongji Hospital, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, Hubei, China
3Department of Surgery, Wuhan 8th Hospital, Wuhan, People’s Republic of China
4Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
5Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
corresponding authorCorresponding author.
#Contributed equally.
Huanlei Wu: wuhuanlei926/at/; Li Xu: lxu1/at/; Jigui Chen: chenjigui/at/; Junbo Hu: jbhu/at/; Shiying Yu: syyu/at/; Guangyuan Hu: h.g.y.121/at/; Liu Huang: huangliu017/at/; Xiaoping Chen: tjchenxp/at/; Xianglin Yuan: yxl/at/; Guojun Li: gli/at/
Received February 20, 2012; Accepted July 3, 2012.
Endogenous estrogens may play a vital role in colorectal tumorigenesis. Estrogen receptor beta is the predominant subtype which mediates the biological effect of estrogens, while loss of expression of estrogen receptor beta has been indicated as a common step in the development of colorectal cancer (CRC). Epidemiological studies have revealed several functional polymorphisms of estrogen receptor beta (ESR2) for cancer risk, but relevant study in CRC is limited, particularly in men. This study aimed to investigate the association of circulating estradiol and variations of ESR2 with CRC risk in men.
We initiated a case–control study consisting of 390 patients with CRC and 445 healthy controls in men only. We genotyped ESR2 single nucleotide polymorphisms (SNPs) rs1256049 and rs4986938 and measured serum estradiol concentration using chemilluminescence immunoassay. Multivariable logistic regression model was performed to evaluate the associations between these variables and CRC risk.
ESR2 rs1256049 CT/TT genotypes were associated with reduced risk of CRC (odds ratio [OR], 0.7, 95% confidence interval [CI], 0.5–1.0), while rs4986938 CT/TT genotypes were associated with increased risk of CRC (OR, 1.5, 95% CI, 1.0–2.1). In addition, the CRC risk increased with the number of risk genotypes of these two SNPs in a dose–response manner (Ptrend, 0.003). Specifically, subjects carrying risk genotypes of both SNPs had the highest risk of CRC (OR, 2.0, 95% CI, 1.3–3.3.). Moreover, serum estradiol concentration alone was associated with risk of CRC in men (OR, 1.2, 95% CI, 1.0–1.3). However, individuals presenting both rs4986938 CT/TT genotypes and high level of serum estradiol had a high risk of CRC (OR, 2.3, 95% CI, 1.4–3.9), compared with those presenting CC genotype and low level of serum estradiol. The similar joint results were not observed for SNP rs1256049.
These results suggest that endogenous estrogen and genetic variations in ESR2 may individually, or more likely jointly, affect CRC risk in male Han Chinese population, while larger studies are needed to validate our findings.
Keywords: Colorectal cancer, Endogenous estrogen, Estrogen receptors, Single nucleotide polymorphisms
Articles from BMC Cancer are provided here courtesy of
BioMed Central